Clinical Trial Watch: Overactive Bladder, BPH

Overactive Bladder

■ Combined Behavioral and Drug Treatment of Overactive Bladder in MenSponsor(s): University of Alabama at Birmingham
Identifier: NCT01175382

■ A Study of the Pharmacokinetics and Pharmacodynamics of MK4618 in Women With OAB (MK-4618-004)Sponsor(s): Merck
Identifier: NCT01500382

■ Botox for the Treatment of OAB Secondary to Benign Prostatic ObstructionSponsor(s): Weill Medical College of Cornell University
Identifier: NCT01220726

■ Refractory OAB: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)Sponsor/Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Duke University; University of Alabama at Birmingham; University of California, San Diego; The Cleveland Clinic; Brown University; University of New Mexico; University of Pennsylvania; University of Pittsburgh; Oregon Health and Science University; RTI International
Identifier: NCT01502956

■ Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic OABSponsor(s): Allergan
Identifier: NCT00439140

■ Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic OAB and Urinary IncontinenceSponsor(s): Allergan
Identifier: NCT01157377

BPH

■ PROLIEVE Post-Marketing Study Treatment of BPHSponsor(s): Boston Scientific Corporation
Identifier: NCT00407953

■ Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic BPHSponsor/Collaborators: Brooklyn Urology Research Group; American Medical Systems; Richard Wolf Medical Instruments Corporation
Identifier: NCT01500057

■ An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for BPHSponsor/Collaborators: Weill Medical College of Cornell University; Pfizer
Identifier: NCT00605319